Biz2X Announces 2025 Frontiers of Digital Finance (FDF) Conference January 13-14, at University of Miami
December 17, 2024 06:07 ET
|
Biz2X
NEW YORK and MIAMI, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biz2X®, a global fintech small business finance platform headquartered in New York that has facilitated over $10 billion in SMB funding to...
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024 16:05 ET
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Proposed Public Offering
December 11, 2024 06:17 ET
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024 12:14 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
September 27, 2023 10:12 ET
|
The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...